Document is current

Any future updates will be listed below

A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel

Crossref DOI link: https://doi.org/10.1007/s00228-025-03905-8

Published Online: 2025-09-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark